Skip to content
Open access

A Comparative Study of Drug-Coated and Plain Balloon Angioplasty for Malfunctioning or Delayed-Maturation Native Arm Arteriovenous Fistulas in Hemodialysis Patients

Oct 2026 · International Journal of Drug Delivery Technology · 0 citations · 5 references

Abstract

Background: The global burden of end-stage renal disease (ESRD) continues to increase, leading to a growing demand for durable hemodialysis vascular access. Percutaneous transluminal angioplasty (PTA) remains the standard treatment for stenotic lesions within the dialysis access circuit; however, the comparative effectiveness of drug-coated balloon (DCB) angioplasty versus plain old balloon angioplasty (POBA) remains uncertain. This study aimed to compare the safety, clinical and radiological outcomes, and overall cost of DCB versus POBA in the management of malfunctioning or delayed-maturation native arteriovenous fistulas (AVFs) over a 12-month follow-up period. Methods: This prospective comparative study included 40 hemodialysis patients with native arm AVFs. Twenty patients underwent DCB angioplasty, and 20 underwent POBA. Clinical outcomes, recurrence rates, thrombosis, primary patency, need for re-intervention, and total procedural costs were assessed over 12 months. Results: Recurrence rates were 20% in the DCB group and 30% in the POBA group. Thrombosis occurred in 10% of patients in each group. Primary patency at 12 months was 90% in both groups. No re-interventions were required in either group during the follow-up period. Although recurrence was numerically lower in the DCB group, the difference was not statistically significant (p = 0.465). Total procedural cost was significantly higher in the DCB group compared with POBA (p < 0.001). Conclusion: DCB angioplasty did not demonstrate a statistically significant clinical advantage over POBA in the treatment of malfunctioning or delayed-maturation native AVFs during the first 12 months of follow-up, while incurring substantially higher costs. These findings support the continued use of POBA as a cost-effective first-line endovascular treatment in this clinical setting. Larger studies with longer follow-up are required to validate these results.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.